Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
International Journal of Molecular Sciences · 27.11.2025 · 26 (23) · 11517
DOI: 10.3390/ijms262311517 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.11.2025. Verfasst von Supriya Peshin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 273 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The advent of targeted therapies has significantly transformed the management of non-small-cell lung cancer (NSCLC), improving survival across all disease stages. Discoveries of both common and rare oncogenic drivers are advancing rapidly, posing a challenge for clinicians and researchers to remain up to date in this dynamic field. This review highlights the evolving landscape of therapeutic strategies for actionable mutations in lung cancer, with particular attention given to the latest developments in KRAS-targeted treatments including non-G12C mutations, pan-RAS inhibitors, and agents targeting RAS-GTP. We also examine the existing standards of care for NSCLC harboring EGFR and ALK alterations, as well as emerging therapies poised for clinical use. Additional discussion includes advancements in therapies directed at MET, HER2, RET, ROS1, and FGFR alterations—each representing promising targets in NSCLC. This review concludes by exploring the growing evidence surrounding TROP-2 as a novel therapeutic target, especially relevant in cases where previous targeted treatments have failed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
- HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA.
- MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
- Department of Pulmonary Critical Care, Norton Community Hospital, Norton, VA 24273, USA.
- Department of Hematology and Oncology, East Tennessee State University, Johnson City, TN 37614, USA.
ORCID-Profile: Supriya Peshin, Ehab Takrori
Zitieren
APA
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A., Mithani, M. S., Anum, F., Asfeen, U., Couch, J. K., Donovan, M., & Singal, S. (2025). Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions. International Journal of Molecular Sciences, 26(23), 11517. https://doi.org/10.3390/ijms262311517
Vancouver
Peshin S, Takrori E, Yazji JH, Haque J, Dharia A, Mithani MS, et al. Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions. International Journal of Molecular Sciences. 2025;26(23):11517. doi:10.3390/ijms262311517
BibTeX
@article{Peshin2025,
author = {Peshin, Supriya and Takrori, Ehab and Yazji, Joseph H and Haque, Johum and Dharia, Adit and Mithani, Mohammad Sajid and Anum, Fnu and Asfeen, Ummul and Couch, Jill Kristen and Donovan, Mabe and Singal, Sakshi},
title = {Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {23},
pages = {11517},
doi = {10.3390/ijms262311517}
}
EUVIMED